Medtronic PLC vs Vistra Corp — how do they compare? Medtronic PLC trades at $87.75 (market cap $112.24B), while Vistra Corp trades at $158.64 (market cap $52.41B). The key difference: Medtronic PLC is far larger — about 2.1× Vistra Corp's market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Vistra Corp for 32 Days on average.
| MDT | VST | |
|---|---|---|
Market Cap | $112.24B | $52.41B |
Volume | 105,663,236 | 11,278,074 |
Sector | Health | Utilities |
52-Week High | $105.35 | $210.85 |
52-Week Low | $73.75 | $134.71 |
Typical Hold Time | 63 Days | 32 Days |
Enterprise Value | $131.58B | $74.34B |
Dividend Yield | 3.28% | 0.59% |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
Vistra Corp (VST) trades at $166.72, up 3.88% with strong analyst support (91% buy ratings) and a $215.23 consensus target. The stock shows bullish technical momentum above key support at $162, while fundamentals reveal impressive 75.73% ROE and 11.55% net margin. Recent developments include a $4.2 billion US loan for nuclear expansion and a 20-year power deal with New Era Energy, positioning VST to capitalize on AI-driven electricity demand.
Vistra offers compelling exposure to the AI power infrastructure theme with strong profitability and government backing, though investors face earnings volatility risks as seen in recent quarterly misses. The stock trades at a premium valuation (P/E 26.33) but maintains upside potential if execution on nuclear expansion and data center contracts meets expectations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →